^
    Back
    Association details:
    Biomarker:AKT1 mutation + ER positive
    Cancer:Breast Cancer
    Drug:Truqap (capivasertib) (AKT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for HER2 Negative Breast Cancer)
    New
    Title:

    Truqap plus Faslodex approved in the EU for patients with advanced ER-positive breast cancer

    Excerpt:
    AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the European Union (EU) for the treatment of adult patients with estrogen receptor (ER)-positive, HER2‑negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN-alterations following recurrence or progression on or after an endocrine-based regimen.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Lancet Oncol
    Title:

    Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

    Published date:
    09/10/2020
    Excerpt:
    Participants were women (aged ≥18 years) with histologically confirmed advanced breast cancer...cohort C comprised patients with AKT1 mutations and oestrogen receptor-positive cancer (treated with oral capivasertib 400 mg plus intramuscular standard-dose fulvestrant)...18 (60%) of 30 patients with an AKT1 mutation in ctDNA and oestrogen receptor-positive cancer were enrolled in cohort C...All 18 patients were evaluable; four (22% [95% CI 6–48]) patients had a confirmed partial response, and an additional four patients had unconfirmed partial responses...
    Secondary therapy:
    fulvestrant
    DOI:
    10.1016/S1470-2045(20)30444-7
    Test:
    Guardant360® CDx